ninth international symposium on regional cancer therapies

For

addi

tion

al in

form

atio

n o

r to

reg

iste

r on

line,

con

tact

:

htt

ps:

//cc

ehs.

up

mc.

com

F e b r u a r y 1 5 – 1 7 , 2 0 1 4

Ninth International Symposium on

Regional Cancer TherapiesSheraton Steamboat Springs

Steamboat Springs, Colorado

Sponsored by

David C. Koch

Regional Cancer Therapy Center

and

University of Pittsburgh School of Medicine

Center for Continuing Education

in the Health Sciences

and

UPMC Cancer Centers

In Collaboration with

The University of Maryland

Marlene and Stewart Greenebaum

Cancer Center

The Medical College of Wisconsin

Cancer Center

Course Co-Directors

H. Richard Alexander, MD

Professor of Surgery

University of Maryland School of Medicine

Baltimore, Maryland

David L. Bartlett, MD



Pittsburgh, Pennsylvania

Robert P. Edwards, MD

Professor, Obstetrics, Gynecology and

Reproductive Sciences


Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS

Associate Professor of Surgery

Medical College of Wisconsin

Milwaukee, Wisconsin

David

C. K

och

Regi

onal

Canc

er T

hera

py C

ente

r

UPM

C Ca

ncer

Pav

ilion,

Sui

te 4

13

5150

Cen

tre A

venu

e

Pitts

burg

h, P

A 15

232

Nonp

rofit

Org

.U.

S. P

osta

gePA

IDPi

ttsbu

rgh,

PA

Perm

it No

. 383

4

Nin

th I

nte

rnat

ion

al S

ympo

siu

m o

n

Reg

ion

al C

ance

r T

hera

pies

Sher

aton

Ste

ambo

at S

prin

gs, S

team

boat

Spr

ings

, Col

orad

o

Fe

br

ua

ry

15

–1

7,

20

14

~ 2 ~ ~ 3 ~

Intent and Overview

This course is designed to cover the most recent advances in cancer therapy that are

primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian

and thoracic. Upon completion of the activity, learners from several disciplines should

be able to discuss the latest regional therapies in surgical oncology.

Who Should Attend

This course is designed for physicians and nurses practicing in the areas of Medical,

Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.

Continuing Education Credit

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council

for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this educational activity for

a maximum of 19.0 AMA PRA Category 1 Credits™. Each physician should claim only

credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 1.90 continuing education units (CEU’s)

which are equal to 19.0 contact hours.

Special Needs

Participation by all individuals is encouraged. Advance notification of any special needs

will help us provide better service. Please notify us of your needs at least two weeks in

advance of the program by calling Maureen Hewko at (412) 623-5993.

Schedule – Saturday, February 15, 2014

6:45 am Registration and Breakfast

7:00 am Welcome

Moderators: Steven Ahrendt, MD and James Cusack, MD

7:15 am Peritoneal Surface Disease with Synchronous Hepatic Involvement

Treated with Cytoreductive Surgery (CRS) and Hyperthermic

Intraperitoneal Chemotherapy (HIPEC)

Andrea Doud, MD, et. al.

7:30 am Nomograms to Predict Prognosis in Pseudomyxoma Peritonei:

A PSOGI Multicenter Study

Shigeki Kusamura, MD, et. al.

7:45 am Extra-appendiceal Origin does not Affect Prognosis in Patients with

Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and HIPEC

Dario Baratti, MD, et. al.

8:00 am Evaluation of a New Staging Classification and a Peritoneal Surface

Disease Severity Score (PSDSS) in 210 Patients with Mucinous

Appendiceal Neoplasms

Jesus Esquivel, MD, et. al.

8:15 am GUEST LECTURER

Comprehensive Palliative Care for Peritoneal Carcinomatosis

Laura Lambert, MD

8:45 am Break with Refreshments/Exhibitors

Moderators: Fabian Johnston, MD and Amer Zureikat, MD

9:00 am Learning Curve and Outcomes of Cytoreductive Surgery and

HIPEC for Peritoneal Malignancies

Patricio Polanco, MD, et. al.

9:15 am HIPEC in Peritoneal Dominant Metastatic Colorectal Cancer

Robert Martin, MD, et. al.

The University of Pittsburgh, as an educational institution and as an employer, values equality of opportunity, human dignity, and

racial/ethnic and cultural diversity. Accordingly, as fully explained in Policy 07-01-03, the University prohibits and will not engage

in discrimination or harassment on the basis of race, color, religion, national origin, ancestry, sex, age, marital status, familial

status, sexual orientation, gender identity and expression, genetic information, disability, or status as a veteran. The University

also prohibits and will not engage in retaliation against any person who makes a claim of discrimination or harassment or who

provides information in such an investigation. Further, the University will continue to take affirmative steps to support and advance

these values consistent with the University’s mission. This policy applies to admissions, employment, and access to and treatment

in University programs and activities. This is a commitment made by the University and is in accordance with federal, state, and/

or local laws and regulations. For information on University equal opportunity and affirmative action programs, please contact:

University of Pittsburgh; Office of Affirmative Action, Diversity, and Inclusion; Carol W. Mohamed, Director (and Title IX, 504 and

ADA Coordinator); 412 Bellefield Hall; 315 South Bellefield Avenue; Pittsburgh, PA 15260; 412-648-7860. For complete details on

the University’s Nondiscrimination Policy, please refer to Policy 07-01-03. For information on how to file a complaint under this

policy, please refer to Procedure 07-01-03.

~ 4 ~ ~ 5 ~

9:30 am What is the Impact of Diaphragmatic Involvement During Cytoreductive

Surgery/HIPEC on Short Term Outcomes?

Bernardo Franssen, MD, et. al.

9:45 am DEBATE

HIPEC for Colorectal Cancer — Investigational vs.

Standard of Care

Garrett Nash, MD and Jesus Esquivel, MD

10:15 am Break Until Evening Session

4:00 pm Poster Viewing and Grading

Moderators: Marilyn Huang, MD and Marcello Deraco, MD

4:30 pm Comparison of MRI and CT for Predicting the Peritoneal Cancer Index

(PCI) Preoperatively in Patients Being Considered for Cytoreductive

Surgical Procedures

Russell Low, MD, et. al.

4:45 pm Association Between Hospital Finances, Payer Mix, and Complications

After HIPEC: Deficiencies in the Current Healthcare Reimbursement

System and Future Implications

Charles Staley, MD, et. al.

5:00 pm Maximal Cytoreduction and Hyperthermic Intraperitoneal

Chemotherapy in Advanced Ovarian Cancer

Paolo Sammartino, MD, et. al.

5:15 pm Intraperitoneal Chemotherapy and Ileostomies in Ovarian Cancer

Gleneara Bates, MD, et. al.

5:30 pm Obesity, Lymphadenectomy, and Survival Outcomes in Intermediate to

High-risk, Early Stage Endometrial Cancer Patients

Faina Linkov, MD, et. al.

5:45 pm Cytoreductive Surgery (CRS) and HIPEC in Patients with Recurrent

Platinum-Resistant Ovarian Carcinoma

C. Komen Brown, MD, et. al.

6:00 pm GUEST LECTURER

Is there a Role for HIPEC in Ovarian Cancer?

C. William Helm, MB.BChir

6:30 pm Light Dinner/Exhibitors

Moderators: Douglas Tyler, MD and Charlotte Ariyan, MD

6:45 pm Establishment of a National Guideline for the Use of Cytoreductive

Surgery and HIPEC in the Treatment of Peritoneal Surface

Malignancies in Austria

Thomas Bachleitner-Hofman, MD, et. al.

7:00 pm Accordion Severity Grading and Aggregate Postoperative

Morbidity Burden of CS-HIPEC in a Community Hospital

Jan Franko, MD, et. al.

7:15 pm Quality of Life After Isolated Limb Infusion for In-transit

Melanoma of the Extremity

Betty Jiang, MD, et. al.

7:30 pm Hyperthermic Isolated Limb Perfusion (ILP) with

Curaxins for Melanoma

Minhyung Kim, MD, et. al.

7:45 pm Isolated Limb Infusion is Feasible at Lower Volume

Regional Cancer Centers

David Jeffcoach, MD, et. al.

8:00 pm DEBATE

First Line Treatment for in Transit Melanoma —

Systemic vs. Regional

Steven O’Day, MD and John Kane III, MD

8:30 pm Evening Session Adjournment

8:45 pm Meet the Speakers Reception

~ 6 ~ ~ 7 ~

Sunday, February 16, 2014


7:00 am Welcome

Moderators: T. Clark Gamblin, MD, MS and Martin Goodman, MD

7:15 am Neutrophil-lymphocyte Ratio: A Simple and Novel Biomarker

for Prediction of Survival After Radioembolization for Metastatic

Colorectal Cancer

Samer Tohme, MD, et. al.

7:30 am Transarterial Chemoembolization for Metastatic Neuroendocrine

Tumors: A Single Institution Review of 197 Patients

Lawrence Shirley, MD, et. al.

7:45 am Hepatic Artery Infusion for Recurrent or Chemoresistant Hepatic

Malignancy

Harold Wanebo, MD, et. al.

8:00 am Quality of Life Improvement and Enhanced Efficacy with Hepatic

Arterial Therapy of Doxorubicin-loaded beads (DEBDOX) in the

Treatment of Liver Metastases from Ocular Melanoma



Radioembolization and Chemoembolization 2014:

Current Status and Future Trends

William Rilling, MD

8:45 am Break with Refreshments/Exhibitors

Moderators: James Pingpank Jr., MD and Joel Baumgartner, MD

9:00 am Results and Feasibility of Sequential Isolated Hepatic Perfusion

and Percutaneous Hepatic Perfusion (PHP) With Melphalan for

Patients with Liver Metastases

Mei Li Kwong, MD, et. al.

9:15 am Radioembolization for Unresectable Colorectal Liver Metastases

Anthony Zacharias, MD, et. al.

9:30 am Post-TACE Neutrophil-to-Lymphocyte Ratio is Predictive of Survival in

Patients with Unresectable Neuroendocrine Liver Metastases

Neil Saunders, MD, et. al.

9:45 am DEBATE

High Grade, High PCI Carcinomatosis:

Is There a Role for CRS and HIPEC?

John Stewart, MD (Yes) and Kiran Turaga, MD (No)

10:15 am Break Until Evening Session

4:00 pm Poster Viewing and Grading

Moderators: C. Komen Brown, MD and Daniel Labow, MD

4:30 pm Outcomes Following Cytoreductive Surgery and HIPEC in 44 Patients

with Peritoneal Mesothelioma

Oliver Shihab, MD, et. al.

4:45 pm Iterative Cytoreductive Surgery and HIPEC for Recurrent Diffuse

Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics

and Survival Outcome

Chukwuemeka Ihemelandu, MD, et. al.

5:00 pm Cytoreductive Surgery with HIPEC for Signet Ring Peritoneal

Malignancies

Sarah McPartland, MD, et. al.

5:15 pm Cytoreductive Surgery and HIPEC in Children and Adolescents:

the First 50 Cases

Andrea Hayes-Jordan, MD, et. al.

5:30 pm Peritoneal Dominant Metastatic Colorectal Cancer


5:45 pm Conversion Gastrectomy after Intravenous Intraperitoneal Paclitaxel

(PTX) Administration with Oral S-1 for Peritoneal Dissemination of

Advanced Gastric Cancer with Malignant Ascites

Joji Kitayama, MD, et. al.

~ 8 ~ ~ 9 ~


Pathologic Classification of PMP — Results of Basingstoke

Consensus Conference

Norman Carr, MD

6:30 pm Light Dinner/Exhibitors

Moderators: Nathan Bahary, MD, PhD and Richard Royal, MD

6:45 pm Neoadjuvant Laparoscopic HIPEC for Peritoneal Metastases from

Gastric Cancer

Yutaka Yonemura, MD, et. al.

7:00 pm Cytoreductive Surgery with HIPEC — an Emerging Treatment Option

for Advanced Goblet Cell Tumors of the Appendix

Yarrow McConnell, MD, et. al.

7:15 pm Heated Intraperitoneal Gemcitabine for Resectable Pancreatic

Carcinoma: Morbidity and Early Survival Data from Two Centers

Lana Bijelic, MD, et. al.

7:30 pm Management of Peritoneal Carcinomatosis in Columbia:

Developing a National Center for Excellence

Fernando Arias, MD, et. al.

7:45 pm Intraperitoneal Chemotherapy is Not Associated with Increased 30-Day

Operative Morbidity and Mortality: A Matched Study of Colorectal

Cancer Patients with and without Intraperitoneal Chemotherapy

Edmund Bartlett, MD, et. al.


Video Demonstration of Five Parietal Peritonectomy Procedures Used

for Cytoreductive Surgery of Peritoneal Metastases

Paul Sugarbaker, MD, FACS, FRCS

8:30 pm American Society of Peritoneal Surface Malignancies

Fourth Annual Meeting

9:30 pm Evening Session Adjournment

Monday, February 17, 2014


Moderators: Jason Foster, MD and Timothy Kennedy, MD

7:00 am Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface

Disease Treated with Cytoreductive Surgery and HIPEC

Andrea Doud, MD, et. al.

7:15 am Morbidity of Abdominal Wall Resections (AWR) and Reconstructions

During Cytoreductive Surgery and HIPEC

Maria Nunez, MD, et. al.

7:30 am Role of Obesity in the Proliferation and Metastasis of Endometrial and

Ovarian Adenocarcinoma

Faina Linkov, MD, et. al.

7:45 am Immunohistochemical Evaluation of Calretinin, Claudin, WT-1,

Podoplanin, CK 5/6, Topoisomerase IIa, MCM7, ER, and PGR in Diffuse

Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray

Marcello Deraco, MD, et. al.


Pre-Clinical Research for Appendiceal Cancer:

Where We’ve Been and Where We Need to Go

Haroon Choudry, MD

8:45 am Break and Exhibitors

Moderators: Brian Loggie, MD and Herbert Zeh III, MD

9:00 am Histologic Changes Associated with HIPEC

Patrick Wagner, MD, et. al.

9:15 am Next Generation Sequencing Reveals Significant Genomic Heterogeneity

in Appendiceal Neoplasms

Laura Lambert, MD, et. al.

9:30 am Oncolytic Vaccinia Virus and Irinotecan Synergize to Improve Treatment

of Colorectal Carcinomatosis

J. Andrea McCart, MD, et. al.

~ 10 ~ ~ 11 ~

9:45 am A New Micronutrient Formulation with Hyperthermic Mitomycin C

Enhances Colorectal Tumor Cell Killing in Vitro

Daniel Cucher, MD, et. al.

10:00 am The Effects of Hyperthermia on Cytotoxicity of Intracavitary

Chemotherapeutic Drugs

Gleneara Bates, MD, et. al.

10:15 am CASE PRESENTATIONS/PANEL DISCUSSION

Case Discussants: H. Richard Alexander, MD, and Edgar Guillermo Flores-Ayala, MD

Cardiac Toxicity Associated with Intraperitoneal Administration

of Mitomycin C

Sarah McPartland, MD, et. al.

Cytoreductive Surgery (CRS) and HIPEC in a Patient with Previous

Kidney/Pancreas Transplant


Rare Presentation of Primary Papillary Serous Carcinoma (PSCP)

in a Male Patient


Cytoreductive Surgery and HIPEC for Desmoplastic Small

Round Cell Tumor

Jason Denbo, MD, et. al.

Combined Systemic and Regional Therapy in a Young Adult with

Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma

Teresa Kim, MD, et. al.

Use of a Treatment Efficacy Score in Predicting Patients at Risk for

Extensive Early Recurrence after CRS and HIPEC for Peritoneal

Carcinomatosis Arising from the Appendix

Nelson Royall, MD, et. al.

11:45 am Announcement and Poster Presentation of Poster Award Winners

11:50 am Conference Adjournment

Poster Presentations

1. Hospital Factors that Contribute to Inpatient Mortality in Patients with Peritoneal Carcinomatosis: Larger Hospitals are Not Better. Evan Glazer, MD, et. al.

2. Old Versus Too Old for Surgery in Patients with Peritoneal Carcinomatosis. Evan Glazer, MD, et. al.

3. Neoadjuvant Pelvic Perfusion May Facilitate Resection of Pelvic Recurrent Rectal Cancer. Harold Wanebo, MD, et. al.

4. Escalation of Socioeconomic Disparities Among Patients with Colorectal Cancer Receiving Advanced Surgical Treatment. Parissa Tabrizian, MD, et. al.

5. Laparoscopic Evacuation of Mucinous Ascites for Palliation in Unresectable Pseudomyxoma Peritonei. Kaitlyn Kelly, MD, et. al.

6. Pancreatic Fistulae in Patients Undergoing Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Distal Pancreatectomy are more Severe than those Undergoing Distal Pancreatectomy Alone. Stephanie Downs-Canner, MD, et. al.

7. Predictors of Progression in Patients with High-Grade Appendiceal or Colorectal Adenocarcinoma After Cytoreductive Surgery and HIPEC. Joel Baumgartner, MD, et. al.

8. Validation of the Peritoneal Surface Disease Severity Score in Patients with Sarcomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. George Salti, MD, et. al.

9. The Role of E2F1 in Well-Differentiated Papillary Mesothelioma of the Peritoneum (WDPMP). Gleneara Bates, MD, et. al.

10. Neutrophil-to-lymphocyte Ratio as a Predictor of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Yttrium-90 Radioembolization. Daniel Sukato, MD, et. al.

11. Central Sarcopenia Does not Predict Occurrence of Clinically Dominant Acute Complication after Cytoreductive Abdominal Surgery in a Community Cancer Center. Shawna Grimm, MD, et. al.

12. Preoperative Ureteral Stenting for Patients Undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Carlos HF Chan, MD, et. al.

13. Current Trends in the Management of Malignant Peritoneal Mesothelioma. John Miura, MD, et. al.

14. Optimizing the Role of the Advanced Practice Provider in a HIPEC program. Deborah Schneider, et. al.

15. Development of a Cytoreductive Surgery and HIPEC Program: The Montefiore Einstein Experience. Oscar Serrano, MD, et. al.

16. Cytoreductive Surgery and HIPEC for Appendiceal Neoplasm: Delay to Treatment without Significant Consequence? Julie Alosi, MD, et. al.

~ 12 ~ ~ 13 ~

17. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: A Systematic Review. Joseph Helm, MD, et. al.

18. Role of Laparoscopy in Patients with Peritoneal Metastases Considered for Cytoreductive Surgery and HIPEC. Thejus Jayakrishnan, MD, et. al.

19. Role of Falciform Ligament and Ligamentum Teres Hepatis Resection in HIPEC. Thejus Jayakrishnan, MD, et. al.

20. Surgical Treatment for Mucinous Appendiceal Patients — The Role of Ostomies in Cytoreductive Surgery. Melanie Ongchin, MD, et. al.

21. Elevation of Alkaline Phosphatase Prior to Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors Predicts a Worse Outcome. Jill Onesti, MD, et. al.

22. Outcomes of Cytoreductive Surgery and HIPEC in Patients with High Grade-High Volume Disseminated Mucinous Appendiceal Neoplasms. Patricio Polanco, MD, et. al.

23. Outcomes of HIPEC Therapy at Low Volume Center. David Lee, MD, et. al.

24. Perioperative Clinical Factors May Predict Ineffectiveness of a Sole Epidural Based Pain Management Regimen for Patients Undergoing Cytoreductive Surgery with HIPEC. Jose Soliz, MD, et. al.

25. Peritoneal Mesothelioma in Mexico? Edgar Guillermo Flores-Ayala, MD, et. al.

26. Peritoneal Carcinomatosis from Lung Cancer: Is Debulking Surgery a Suitable Option in Selected Patients. Simone Sibio, MD, et. al.

27. Sentinel Node Biopsy Under Local Anesthesia: The European Institute of Oncology Experience. Alessandro Testori, MD, et. al.

28. Another Unusual Application of Cytoreductive Surgery and Hyperthermic Perioperative Chemotherapy to Definitely Treat a Rare Disease. Paul Sugarbaker, MD, et. al.

29. Prognostic Significance of Clinicopathological Parameters in Diffuse Malignant Peritoneal Mesothelioma. Sandy Liu, MD, et. al.

30. Immunotherapeutic Intra-arterial Adoptive Transfer In a Murine Model. Asher Blum, MD, et. al.

31. A Systematic Review and Meta-Analyses of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Lucas Boehm, MD, et. al.

32. Modified Vesicular Stomatitis Virus as Treatment of Peritoneal Surface Dissemination of Colorectal Cancer. Michelle L. Bryan, MD, et. al.

33. Concomitant Plural and Peritoneal Malignant Mesotheliomas: A single Institution Experience of 10 Cases. Jennifer Collins, MD, et. al.

34. Failure to Rescue in the Surgical Oncology Population. Katherine Kiolbasa, MD, et. al.

35. Survival, Morbidity and Peritoneal Carcinomatosis Index. Horacio Lopez-Basave, MD, et. al.

Course Co-Directors

H. Richard Alexander, MD


University of Maryland School of Medicine

Baltimore, MD

David L. Bartlett, MD



Robert P. Edwards, MD

Professor, Obstetrics, Gynecology and

Reproductive Sciences


T. Clark Gamblin, MD, MS

Stuart D. Wilson Chair in Surgical Oncology

Chief, Division of Surgical Oncology



Milwaukee, WI

Invited Faculty

Steven Ahrendt, MD



Charlotte Ariyan, MD


Memorial Sloan-Kettering Cancer Center

New York, NY

Nathan Bahary, MD, PhD

Associate Professor of Medicine

Division of Medicine and Oncology


Joel Baumgartner, MD

University of California San Diego

La Jolla, CA

C. Komen Brown, MD

Cancer Treatment Centers of America

Zion, IL

Norman Carr, MD

Faculty of Medicine,

University Hospital of Southampton

Southampton, UK

Haroon Choudry, MD

Assistant Professor of Surgery


James C. Cusack, MD


Harvard Medical School

Massachusetts General Hospital

Boston, MA

Marcello Deraco, MD

Surgical Oncologist

Fondazione IRCCS Instituto

Nazionale dei Tumori

Milano, Italy

Jesus Esquivel, MD

Medical Director, International

Oncology Initiatives

Cancer Treatment Centers of America

Philadelphia, PA

Jason Foster, MD


University of Nebraska

Omaha, NE

Martin Goodman, MD


Tufts Medical Center

Boston, MA

C. William Helm, MB.BChir

Consultant Gynaecological Oncologist,

Northern Gynaecological Oncology Centre,

Queen Elizabeth Hospital,

United Kingdom

Marilyn Huang, MD

Assistant Professor


~ 14 ~ ~ 15 ~

Fabian Johnston, MD



Milwaukee, WI

John M. Kane III, MD

Associate Professor of Oncology

Roswell Park Cancer Institute


University at Buffalo

Buffalo, NY

Timothy Kennedy, MD


Montefiore Medical Center

New York, NY

Daniel Labow, MD

Associate Professor

Mt. Sinai School of Medicine

New York, NY

Laura Lambert, MD

University of Massachusetts

Memorial Medical Center

Worcester, MA

Brian Loggie, MD


University of Nebraska

Omaha, NE

Garrett Nash, MD


Memorial Sloan Kettering Cancer Center

New York, NY

Steven J. O’Day, MD

Beverly Hills Cancer Center

Department of Medical Oncology

Los Angeles, CA

James Pingpank Jr., MD



William Rilling, MD



Milwaukee, WI

Richard Royal, MD

Associate Professor

MD Anderson Cancer Center

Houston, TX

John H. Stewart, MD


Wake Forest University

Winston-Salem, NC

Paul H. Sugarbaker, MD

Director, Program in Peritoneal

Surface Malignancy

Washington Hospital Centre

Washington, DC

Kiran Turaga, MD



Milwaukee, WI

Douglas S. Tyler, MD


Duke University

Durham, NC

Herbert J. Zeh III, MD



Amer Zureikat, MD



Faculty for this activity has been required to

disclose all relationships with any proprietary

entity producing health care goods or services.

Faculty reside in the Pittsburgh, Pennsylvania,

metropolitan area unless indicated otherwise.

Abstract/Poster Presenters

Julie Alosi, MD


Buffalo, NY

Fernando Arias, MD

Hospital Universitario Fundacion

Santa Fe de Bogota

Bogota, Colombia

Thomas Bachleitner-Hoffman, MD

Medical University of Vienna

Vienna, Austria

Dario Baratti, MD

Milan Tumor Institute

Milan, Italy

Edmund Bartlett, MD

Hospital of the University of Pennsylvania

Philadelphia, PA

Gleneara Bates, MD

Columbia University Medical Center

New York, NY

Lana Bijelic, MD

Washington Hospital Center

Washington, DC

Asher Blum, MD


Buffalo, NY

Lucas Boehm, MD


Milwaukee, WI

Michelle L. Bryan, MD

Wake Forest Baptist Health

Winston-Salem, NC

Carlos HF Chan, MD


Boston, MA

Jennifer Collins, MD

University of Maryland Medical Center

Baltimore, MD

Daniel Cucher, MD

University of Arizona

Tucson, AZ

Jason Denbo, MD

University of Tennessee Health

Sciences Center

Memphis, TN

Andrea Doud, MD

Wake Forest Baptist Health

Winston-Salem, NC

Stephanie Downs-Canner, MD

UPMC Shadyside

Pittsburgh, PA

Edgar Guillermo Flores-Ayala, MD

Hospital Regional de Alta Especilidad

de Oaxaca

Oaxaca, Oaxaca, Mexico

Jan Franko, MD

Mercy Medical Center

Des Moines, IA

Bernardo Franssen, MD

Mount Sinai School of Medicine

New York, NY

Evan Glazer, MD

The University of Arizona

Tucson, AZ

Shawna Grimm, MD


Des Moines, IA

Andrea Hayes-Jordan, MD

Assistant Professor of Pediatric Surgery

University of Houston MD Anderson

Cancer Center

Houston, TX

~ 16 ~ ~ 17 ~

Joseph Helm, MD


Milwaukee, WI

Chukwuemeka Ihemelandu, MD

Medstar Washington Hospital Center

Washington, DC

Thejus Jayakrishnan, MD


Milwaukee, WI

David Jeffcoach, MD

University of Tennessee Medical Center

Knoxville, TN

Betty Jiang, MD

Duke University Medical Center

Durham, NC

Kaitlyn Kelly, MD

University of California San Diego

La Jolla, CA

Minhyung Kim, MD


Buffalo, NY

Teresa Kim, MD


Boston, MA

Katherine Kiolbasa, MD

Froedtert Hospital

Milwaukee, WI

Joji Kitayama, MD

University of Tokyo

Tokyo, Japan

Shigeki Kusamura, MD

Istituto Nazionale Tumori di Milano

Milano, Italy

Mei Li Kwong, MD

National Cancer Institute, NIH

Bethesda, MD

David Lee, MD

St. Luke’s Roosevelt Hospital

New York, NY

Faina Linkov, MD

University of Pittsburgh

Pittsburgh, PA

Sandy Liu, MD

University of Maryland Medical Center

Baltimore, MD

Horacio Lopez-Basave, MD

Instituto Nacionale de Cancerologia

de Mexico

Distrito Federal, Mexico

Russell Low, MD

Sharp Memorial Hospital

San Diego, CA

Robert Martin, MD

University of Louisville

Louisville, KY

J. Andrea McCart, MD

Toronto General Research Institute

Toronto, Ontario, Canada

Yarrow McConnell, MD

University of Calgary

Calgary, Alberta, Canada

Sarah McPartland, MD

Tufts Medical Center

Boston, MA

John Miura, MD


Milwaukee, WI

Maria Nunez, MD


Baltimore, MD

Jill Onesti, MD

The Ohio State University

Columbus, OH

Melanie Ongchin, MD


Pittsburgh, PA

Patricio Polanco, MD


Pittsburgh, PA

Nelson Royall, MD

MD Anderson Cancer Center Orlando

Orlando, FL

George Salti, MD

The University of Illinois at Chicago

Chicago, IL

Paolo Sammartino, MD

University of Rome

Rome, Italy

Neil Saunders, MD

The Ohio State University

Columbus, OH

Deborah Schneider


Milwaukee, WI

Oscar Serrano, MD

Montefiore-Einstein Center for Cancer Care

Bronx, NY

Oliver Shihab, MD

North Hampshire Hospital

Basingstoke, UK

Lawrence Shirley, MD

Ohio State University

Columbus, OH

Simone Sibio, MD

University Sapienza of Rome

Rome, Italy

Jose Soliz, MD

MD Anderson Cancer Center

Houston, TX

Charles Staley, MD

Emory University

Atlanta, GA

Daniel Sukato, MD


Pittsburgh, PA

Parissa Tabrizian, MD

Mount Sinai Medical Center

New York, NY

Alessandro Testori, MD

European Institute of Oncology

Milan, IT

Samer Tohme, MD


Pittsburgh, PA

Patrick Wagner, MD

Winchester Medical Center

Winchester, VA

Harold Wanebo, MD

Landmark Medical Center

Woonsocket, RI

Yutaka Yonemura, MD

Haruki-Moto-Machi

Kishiwada, Osaka, Japan

Anthony Zacharias, MD


Milwaukee, WI

~ 18 ~ ~ 19 ~

Registration Information

Online Registration is accepted until February 14, 2014. After this date, you are only

able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS

conferences.

Visit our online registration site at https://ccehs.upmc.com. Scroll down to the Ninth

International Symposium on Regional Cancer Therapies section on the web page.

• Click the registration button and enter all of the requested information.

• After registering, an electronic confirmation will be sent to the email address you

provided when you registered.

Registration is not complete until you receive the confirmation email for your

preregistration. If you do not receive this letter within 5-7 days of registration, please

contact Maureen Hewko at (412) 623-5993.

You must bring this confirmation with you to the conference.

Registration Cancellation

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition

cancellations postmarked or date stamped before January 15, 2014 will be completely

refunded. After January 15, 2014, a $35 administrative fee will be assessed. No refunds

will be made after February 1, 2014.

Conference contact for cancellation requests:

Maureen Hewko, MBA

UPMC Cancer Pavilion 413, 5150 Centre Avenue

Pittsburgh, PA 15232

Email: [email protected] • Telephone: (412) 623-5993

Fax: (412) 692-2520

Registration Fees

$300 Physicians and researchers

$200 Nurses and other health care professionals

Registration fee includes:

• Continuing education credit

• Registration and course materials

• Continental breakfast, refreshments and a light dinner

Meeting Location

The conference will be held at the Sheraton Steamboat

Springs, 2220 Village Inn Court, PO Box 774808.

Conference reservations are at the sole responsibility

of the attendees who may contact the hotel.

If registering for a room at the hotel online, please go to https://www.starwoodmeeting.

com/StarGroupsWeb/booking/reservation?id=1308271577&key=5F82A

If you wish to make your reservation by phone, please call John at 970-871-6550 and

ask for the UPP room block.

Accommodations

Nightly Guest Room Rates: $289 per night

Note: Resorts room rates are subject to additional taxes and resort fees as applicable.

Transportation

For up-to-date transportation information, go to the Koch Center Website:

http://www.regionaltherapies.com

For additional information, contact:

Maureen Hewko, MBA

Telephone: (412) 623-5993

Fax: (412) 692-2520

Email: [email protected]

Koch Center Website: http://www.regionaltherapies.com

Visit the Center for Continuing Education

in the Health Sciences Web Site

Our Internet address is: https://ccehs.upmc.com

The UPMC Center for Continuing Education in the Health Sciences invites you to visit

our web location. Receive information on CME programs, earn CME credits on the

Internet, and access information about our formal courses and much more. Discover

who we are and how you can contact us. Please visit our web location often to get

updated information on upcoming programs.

ninth international symposium on regional cancer therapies

Health & Medicine